Skip to main content

Table 2 Delphi 3 Responses

From: Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus

PROBLEM-TREATMENT

MEAN

MEDIAN

CONFIDENCE INTERVAL AROUND MEDIAN (α = 0.05)

   

Lower Limit

Upper Limit

Uveitis (JRA, sarcoid, or idiopathic) unresponsive to MTX treated with infliximab

2.86

2

1

3

Systemic onset JRA treated with anakinra

3.68

3

3

4

Pediatric SLE treated with MMF

4.15

4

3

5

JDM unresponsive to prednisone and DMARDS treated with etanercept

4.59

4

4

6

Systemic onset JRA treated with thalidomide

4.28

5

3

5

Thrombocytopenia unresponsive to standard therapy in SLE treated with rituximab

4.57

5

4

5

Localized Scleroderma treated with steroids and MTX

4.88

5

4

6

Pauci-articular JRA with uveitis, with early treatment

6.97

8

8

8

  1. JRA: Juvenile Rheumatoid Arthritis
  2. MTX: Methotrexate
  3. SLE: Systemic Lupus Erythematosus
  4. MMF: Mycophenolate mofetil
  5. JDM: Juvenile Dermatomyositis
  6. DMARDS: Disease-Modifying Anti-Rheumatic Drugs